Corium Presents Clinical Results from Pilot Bioequivalence Study of Corplex™ Donepezil Transdermal System at Alzheimer's Association International Conference® 2017
Today's poster presentation can be accessed at the Events & Presentations section of Corium's website here.
As announced on
"These data support once-weekly Corplex Donepezil as a bioequivalent alternative to daily Aricept," said
The pilot BE study was a six-month, three-period, randomized crossover study comparing the steady-state pharmacokinetic profiles of once-daily oral Aricept with two Corplex Donepezil transdermal patches that differed only in size.
Corium is planning to start its pivotal BE study later this year and remains on track to file a Section 505(b)(2) New Drug Application (NDA) for the product candidate in 2018. The pivotal study will be a simpler, two-way crossover design compared to the three-way crossover pilot study.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our proprietary products and product candidates. Forward-looking statements are based on management's current expectations and projections and are subject to
risks and uncertainties, which may cause Corium's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Corium's business and its results are detailed in Corium's Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed with the Securities and Exchange Commission (SEC) on
MicroCor® are registered trademarks of
Aricept® is a registered trademark of
Investor and Media Contact:
SMP Communications Susan M. Pietropaolosusan@smpcommunications.com (201) 923-2049
News Provided by Acquire Media